Detailed answers, not pamphlet copy.

All treatments are performed or directly supervised by licensed medical providers — board-certified physicians, nurse practitioners, and registered nurses with documented device-specific training. Energy-based and injectable procedures are not delegated to unlicensed staff.

Every new patient receives a one-on-one consultation that includes skin analysis (Fitzpatrick typing, photodamage assessment, laxity grading), medical history review, and goal alignment. We then build a protocol that sequences modalities — for example, IPL for pigment before Morpheus8 for texture — rather than recommending a single device for every concern.

Yes. Every energy-based device in the practice — InMode Optimas, Ultherapy PRIME, STEMWAVE, Tetra Pro, and Exion — carries an active FDA 510(k) clearance for its respective indication. Injectables used are FDA-approved.

It means three things: a physician is responsible for the medical practice, treatments are performed with prescription-class devices not available in non-medical settings, and protocols (energy settings, pass count, intervals) are documented in your clinical chart for continuity.

Some medical wellness services — such as physician-supervised GLP-1 programs and certain medically indicated dermatologic treatments — may be HSA or FSA eligible. Cosmetic-only procedures generally are not. We can provide itemized receipts; eligibility is ultimately determined by your plan administrator.

We do not advertise compounded GLP-1s, weight-loss outcomes, or off-label use. Our GLP-1 program is described as a physician-supervised medical service, with eligibility, dosing, and monitoring determined during clinical intake — consistent with current FDA marketing guidance.

Downtime is procedure-specific and ranges from zero (Forma, Lumecca, Ultherapy) to 1–3 days of redness and pinpoint scabbing (Morpheus8, Tetra Pro CoolPeel). Detailed pre- and post-care instructions are provided at the time of booking.

Standardized clinical photography (consistent lighting, angle, and distance) at baseline and at protocol-defined intervals. For tightening protocols, we also track clinician-rated laxity grading and patient-reported satisfaction at 90 and 180 days.